Pfizer announces positive results from Phase 3 Study of Abrysvo
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Total value of the supplies of FC will be US$ 2.773 million
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Highly effective preservation solutions ensuring the safety and protection of personal care products
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Subscribe To Our Newsletter & Stay Updated